When FDA Trust Is Broken: Lessons from the MedLink Scandal

Ariana Wilson and Mark Drlik seated against a white background, wearing lavalier microphones. The woman on the left has long brown curly hair and is wearing a beige cardigan over a taupe top. The man on the right is wearing glasses and a blue button-up shirt. They appear to be engaged in conversation or a video interview.
Resources

When FDA Trust Is Broken: Lessons from the MedLink Scandal

Sector: Diagnostics

A recent FDA announcement has sent shockwaves through the MedTech community: MedLink, a third-party test house, was found falsifying test data. The consequences? All pending FDA submissions that relied on MedLink’s data have been rejected, delaying or derailing device approvals and costing companies precious time and trust.

In this episode of MedDevice by Design, Ariana Wilson and Mark Drlik examine what happened, what it means for medical device innovators, and how the FDA’s ASCA (Accreditation Scheme for Conformity Assessment) program helps reduce regulatory risk.

The FDA discovered that MedLink had falsified testing data, compromising the integrity of submissions relying on that information. As a result, those submissions are now invalid, and the affected companies must retest their devices and resubmit, costing them months of delay and significant financial loss.

Why ASCA Accreditation Matters

To prevent this kind of disruption, the FDA established the ASCA program in 2020. Labs that receive ASCA accreditation are thoroughly vetted, giving the FDA and submitting companies greater confidence in their test results. Submissions that include ASCA-accredited data benefit from reduced review times—sometimes shaving weeks or even months off approval timelines.

The Tradeoff: Fewer Labs, Higher Costs

As of late 2024, only 47 test houses hold ASCA accreditation, limiting access for some companies. Additionally, ASCA-accredited testing can be 10% to 30% more expensive than non-accredited alternatives. Still, that investment offers peace of mind and regulatory security—especially when the risk of working with an unreliable lab is so high.

Key Takeaway: Prioritize Risk Management


This episode is a reminder of the critical role third-party labs play in the regulatory process. Choosing an ASCA-accredited lab is not just about speed; it’s about reducing risk, protecting your investment, and ensuring trust in your data.

Learn more about StarFish Medical.

X-ray image of a human chest showing bones in high contrast. A visible electronic device, likely a pacemaker or implant, is located in the upper left chest area. A bold red arrow points to the device with a label in black and white text reading “definitely not bone.”

Why Barium Sulfate Is a MedTech Powerhouse

Mark and Ariana explore the surprising versatility of barium sulfate—a material used widely in both diagnostic procedures and medical device manufacturing. While many recognize it as the contrast agent you drink before an X-ray, it’s also a key additive that enhances plastic components across the healthcare industry.

Gloved hand holding a test tube filled with red liquid, with a large red arrow pointing at the tube on a blue gradient background.

Alzheimer’s Blood Test for Early Detection

We explore a groundbreaking shift in how Alzheimer’s disease may soon be diagnosed. Instead of relying on invasive spinal taps or costly PET scans, researchers have developed a blood test that detects key proteins associated with the disease—offering a more accessible and patient-friendly screening method.

A bearded man in a denim shirt uses a handheld breathalyzer device. To the left, bold text reads: "How Breath Testing REALLY works," with the word "REALLY" emphasized in bright purple.

Breath Testing in Medical Devices: From Impairment to Gut Health

We explore how breath testing in medical devices is transforming diagnostics. Mark Drlik walks through how this technology supports everything from roadside impairment detection to gastrointestinal analysis.

A transparent capsule-shaped ingestible medical device is shown on the right, revealing internal electronics, circuits, and components. On the left, bold purple text reads “Ingestible Medical Devices” against a clean white background.

Ingestible Capsules: Future of GI Diagnostics and Drug Delivery

Mark Drlik and Ariana Wilson introduce the fascinating world of ingestible capsules—tiny, swallowable medical devices that are revolutionizing gastrointestinal health monitoring and targeted therapy.